Arbutus (ABUS) Q2 Revenue Surges 529%

Arbutus Biopharma (NASDAQ:ABUS), a biotechnology firm focused on treatments for chronic hepatitis B and RNA-based medicines, delivered GAAP results for Q2 2025 that greatly outpaced analyst expectations. The August 6, 2025 release showed GAAP revenue of $10.7 million, far above the $1.59 million estimate, and GAAP EPS of $0.01 compared to the projected $(0.05). This outperformance stemmed from the one-time recognition of deferred revenue after the termination of its Qilu Pharmaceutical partnership. Operating expenses (GAAP) tumbled year over year, and restructuring actions sharply improved near-term profitability, resulting in GAAP net income of $2.5 million. While results beat forecasts, the main driver was a non-recurring event (the recognition of previously deferred revenue following the conclusion of the Qilu Pharmaceutical partnership), rather than sustainable operational growth, making this quarter unique within the company's financial trajectory. Source: Analyst estimates for the quarter provided by FactSet. Arbutus Biopharma is a clinical-stage biotechnology company developing therapies targeting chronic hepatitis B virus (cHBV) and leveraging lipid nanoparticle (LNP) delivery technology. Its leading assets are imdusiran, an RNA interference (RNAi) therapeutic aiming to silence HBV antigens, as well as AB-101, an oral PD-L1 inhibitor.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool